Pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies.

The design and development of therapeutic monoclonal antibodies through optimizing their pharmacokinetic (PK) and pharmacodynamic (PD) properties is crucial to improve efficacy while minimizing adverse events. Many of these properties are interdependent, which highlights the inherent challenges in therapeutic antibody design, where improving one antibody property can sometimes lead to changes in others. Here, we discuss optimization approaches for PK/PD properties of therapeutic mAbs. This article is protected by copyright. All rights reserved.